ADRX · ISSUER CIK 1802369
ADARx Pharmaceuticals, Inc.
Between Jul 31, 2026 and Oct 28, 2026, 6 ADARx Pharmaceuticals, Inc. insiders reported $87.7M of open-market purchases and $0.00 of sales on SEC Form 4. The largest buyer was Sr One Capital Management, LLC (10% Owner), with $27.2M.
↗6 insiders filed
Original Form 4 filings from Jul 31, 2026 to Oct 28, 2026. No open-market sales in the window.
$87.7MInsider buying
$0.00Insider selling
+$87.7MNet open-market
Sep 30, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 202617:29 | Sep 28, 2026 | ADRX | Director | P · Buy | $17.00 | +61,516 | 9,292,025 | +1% | +$1.0M | -12.1% | +5.6% |
| Sep 30, 202617:29 | Sep 28, 2026 | ADRX | Director | C · Convert | — | +9,230,509 | 9,230,509 | New | — | ||
| Sep 30, 202617:25 | Sep 28, 2026 | ADRX | Director, 10% Owner | P · Buy | $17.00 | +950,000 | 588,235 | — | +$16.1M | -12.1% | +5.6% |
| Sep 30, 202617:25 | Sep 28, 2026 | ADRX | Director, 10% Owner | C · Convert | — | +23,255,789 | 9,230,509 | — | — | ||
| Sep 30, 202617:23 | Sep 28, 2026 | ADRX | Director, 10% Owner · +4 joint | P · Buy | $17.00 | +950,000 | 588,235 | — | +$16.1M | -12.1% | +5.6% |
| Sep 30, 202617:23 | Sep 28, 2026 | ADRX | Director, 10% Owner · +4 joint | C · Convert | — | +23,255,789 | 9,230,509 | — | — | ||
| Sep 29, 202621:45 | Sep 28, 2026 | ADRX | 10% Owner | P · Buy | $17.00 | +1,600,000 | 592,593 | — | +$27.2M | -12.1% | +5.6% |
| Sep 29, 202621:45 | Sep 28, 2026 | ADRX | 10% Owner | C · Convert | — | +8,336,661 | 1,836,469 | — | — | ||
| Sep 29, 202621:43 | Sep 28, 2026 | ADRX | Director, 10% Owner | P · Buy | $17.00 | +1,600,000 | 592,593 | — | +$27.2M | -12.1% | +5.6% |
| Sep 29, 202621:43 | Sep 28, 2026 | ADRX | Director, 10% Owner | C · Convert | — | +8,336,661 | 1,836,469 | — | — | ||
| Sep 29, 202621:38 | Sep 28, 2026 | ADRX | 10% Owner · +2 joint | C · Convert | — | +11,858,655 | 11,243,179 | — | — |